No, and the binder (for FT825) was licensed to Ono Pharma who have a collaboration with FATE. It was established in Sept 2018 and expanded in June 2022 for a second undisclosed antigen target for solid tumours.
As for the 1XX co-stim, FATE licensed it from MSKCC.
Market Data 
Markets 
AI
